CHINESE JOURNAL OF DRUG EVALUATION >

2025 , Vol. 42 >Issue 5: 378 - 378-383

DOI: https://doi.org/magtech-2025-09-19-00001

Bufei Wan for the Treatment of Post-Viral Pneumonia Pulmonary Function Impairment and Nodules

Expand
  • 1.First Clinical Medical College， Beijing University of Chinese Medicine， Beijing 100700， China；
    2.Dongzhimen Hospital， Beijing University of Chinese Medicine， Beijing 100700， China；
    3.Beijing Center for Integrative Oncology Minimally Invasive Medicine， Beijing 101121， China

Received date: 2025-09-19

  Revised date: 2025-10-11

  Accepted date: 2025-11-27

  Online published: 2025-12-15

Fold

Abstract

Objective： To investigate the effects of Bufei wan on pulmonary function and pulmonary nodules in patients with Qi-yin deficiency following viral pneumonia. Methods： A total of 68 patients with Qi-yin deficiency syndrome after viral pneumonia， treated at the International Department of the Hospital between July 2023 and December 2024， were enrolled. A self-controlled design was adopted. Patients were administered Bufei wan orally for 30 d. Changes in traditional Chinese medicine (TCM) symptom scores， pulmonary function， pulmonary nodules， and safety indicators before and after treatment were observed. Results： After treatment， TCM symptom scores improved significantly (P<0.005). Clinical efficacy of TCM symptoms showed 0 cases cured， 2 markedly effective， 47 effective， and 19 ineffective. Vital capacity percentage (VC%)， forced vital capacity percentage (FVC%)， and forced expiratory volume in one second percentage (FEV1%) as well as FEV1/FVC showed improvement compared with before treatment (P<0.01). Although maximal voluntary ventilation percentage (MVV%) also improved， the difference was not statistically significant (P=0.061). The cross-sectional area of pulmonary nodules decreased significantly after treatment (P<0.05)， although the reduction in nodule number was not statistically significant (P=0.895). Efficacy evaluation of pulmonary nodules showed 3 cases cured， 2 markedly effective， 7 effective， 9 stable， and 0 progressed. No serious adverse events occurred during treatment. Conclusion： This study demonstrates that a one-month treatment with Bufei wan effectively improved TCM symptoms such as cough， expectoration， dyspnea， chest tightness， and shortness of breath in patients with Qi-yin deficiency after viral pneumonia. It also enhances multiple pulmonary function parameters and contributes to the reduction of pulmonary nodule cross-sectional area. No serious adverse events occurred during treatment， indicating good safety. Bufei Wan may serve as an adjuvant therapy for promoting pulmonary function recovery and nodule improvement in this patient population.

Key words： ; font-size:medium; ">Bufei wan； Pulmonary nodules； Viral pneumonia； Pulmonary function； Qi-yin deficiency

Cite this article

WU Yichao, SONG Lianying, YU Xudong, FU Yuewan, ZHOU Bingxin, YAN Shaoshuai, WANG Xingqi, HUO Yuan, ZHAO Xiaoxuan, LOU Baoyi, ZHANG Yaosheng . Bufei Wan for the Treatment of Post-Viral Pneumonia Pulmonary Function Impairment and Nodules[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(5) : 378 -378-383 . DOI: magtech-2025-09-19-00001

References

[1] Shang L， Xu J， Cao B. Viral pneumonia in China： from surveillance to response[J]. Lancet Public Health， 2020， 5(12)： e633-e634.
     [2] Ruuskanen O， Lahti E， Jennings L C， et al. Viral pneumonia[J]. Lancet， 2011， 377(9773)： 1264-1275.
     [3] Zhou F， Wang Y， Liu Y， et al. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults： a multicentre prospective registry study from the CAP-China Network[J]. Eur Respir J， 2019， 54(2)：1802406.
     [4] 世界中医药学会联合会内科专业委员会.社区获得性肺炎中西医结合诊疗指南[J]. 中国循证医学杂志，2025，25(1)：32-41.
     [5] Davis HE， McCorkell L， Vogel JM， et al. Long COVID： major findings， mechanisms and recommendations[J]. Nat Rev Microbiol， 2023， 21(3)： 133-146.
     [6] 屈小艳，赵明栋.肺结节病因及形成机制的研究进展[J]. 河南大学学报（医学版），2024，43(3)：162-167.
     [7] 杨江，李建生，陈耀龙，等.中成药治疗成人社区获得性肺炎临床应用指南（2025版）[J]. 中国全科医学，2025，28(20)：2464-2480.
     [8] 中华中医药学会内科分会，李建生，冯贞贞，等.新型冠状病毒肺炎中医证候诊断标准(试行) [J]. 中医杂志，2021，62(1)： 86-90.
     [9] 金一顺，李芹，洪美珠，等.新冠肺炎患者恢复期中医诊疗思路总结[J]. 福建中医药，2022，53(6)：4-5.
     [10] 陆权，王雪峰，钱渊，等.儿童病毒性肺炎中西医结合诊治专家共识(2019年制定) [J]. 中国实用儿科杂志，2019，34(10)：801-807.
     [11] 葛均波.内科学[M]. 第10版.北京：人民卫生出版社，2024：53-56.
     [12] 李梦乾，姜良铎，张晓梅，等.肺结节中医药临床疗效评价体系探讨[J]. 北京中医药大学学报，2023，46(10)：1333-1337.
     [13] Dandachi D， Rodriguez-Barradas MC. Viral pneumonia： etiologies and treatment[J]. J Investig Med， 2018， 66(6)： 957-965.
     [14] Pagliano P， Sellitto C， Conti V， et al. Characteristics of viral pneumonia in the COVID-19 era： an update[J]. Infection， 2021， 49(4)： 607-616.
     [15] Fumagalli A， Misuraca C， Bianchi A， et al. Pulmonary function in patients surviving to COVID-19 pneumonia[J]. Infection， 2021， 49(1)： 153-157.
     [16] Snoeckx A， Reyntiens P， Desbuquoit D， et al. Evaluation of the solitary pulmonary nodule： size matters， but do not ignore the power of morphology[J]. Insights Imaging， 2018， 9(1)： 73-86.
     [17] Cruickshank A， Stieler G， Ameer F. Evaluation of the solitary pulmonary nodule[J]. Intern Med J， 2019， 49(3)： 306-315.
     [18] 李富云，南丽丽，李待军，等.党参本草考证[J]. 中国野生植物资源，2023， 42(9)：105-113.
     [19] Salehi S， Reddy S， Gholamrezanezhad A. Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19)： What we know and what to expect[J]. J Thorac Imaging， 2020， 35(4)： W87.
     [20] Febbo J， Revels J， Ketai L. Viral pneumonias[J]. Radiol Clin North Am， 2022， 60(3)： 383-397.
     [21] 赵佳琪，刘馨泽，孙莹，等.党参化学成分的提取分离及药理活性研究进展[J]. 中华中医药学刊，2025.
     [22] 付慧婕，雷根平，董盛，等.黄芪的现代药理作用及研究进展[J]. 河北中医， 2025，47(4)：695-699，704.
     [23] Su XD， Jang HJ， Wang CY， et al. Anti-inflammatory potential of saponins from aster tataricus via NF-κB/MAPK activation[J]. J Nat Prod， 2019， 82(5)： 1139-1148.
     [24] 郑历史，孙淑仃，刘学芳.紫菀的化学成分及在慢性阻塞性肺疾病中的应用研究进展[J]. 辽宁中医药大学学报，2025-07-21.
     [25] 于子柠，左军.五味子炮制的历史沿革及药理作用研究进展[J]. 辽宁中医药大学学报，2025，44（7）：64-70.
     [26] 蒋海生，王佳丽.桑白皮的药理作用及临床应用研究进展[J]. 中药与临床， 2021，12(2)：79-82.
     [27] 姚辛敏，关慧波.地黄化学成分及药理作用研究进展[J]. 中医药信息，2025， 42(1)：84-89.
     [28] Xiao YD， Lv FJ， Li WJ， et al. Solitary pulmonary inflammatory nodule： CT features and pathological findings[J]. J Inflamm Res， 2021， 14： 2741-2751.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]